The names on this page are hidden. Create a free account to reveal 5 records a month, or get Venture Capital Intelligence at $199 a month for every name. Every figure, date and source on this page is public either way.

Companies / A••••• T•••••••••

A••••• T•••••••••

Series AUSPharmaceuticals
Facts
Year of incorporation
2023sec.gov
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
$197Msum of rounds with a disclosed amount only
Named investors
4
Financing history
2 rounds
  1. Feb 24, 2026
    Series A · $197M (disclosed)
    S••••• C•••••• (participant)K•••• P••••••• (participant)A•••• B••••••••• C•••••• (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “A••••• T••••••••• Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metab”
  2. Dec 22, 2025
    Form D equity offering · $56.9M (form d sold) · 17 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “A••••• T•••••••••, Inc. filed Form D: $56,862,480 sold of $110,724,980, Pharmaceuticals”
Investors on record
4 edges
People
1 officers, 7 directors
Timeline
2
  1. Feb 24, 2026
    A••••• T••••••••• announced Series A of $197,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
  2. Jan 14, 2026
    A••••• T•••••••••, Inc. filed Form D: $56,862,480 sold of $110,724,980, Pharmaceuticals
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
17 observations
Every observation on this company